BACK
|Enrolling,Heart Failure
Power HF
The purpose of this study is to evaluate the efficacy of the medication JTT-861 administered for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF).
The purpose of this study is to evaluate the efficacy of the medication JTT-861 administered for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF).